Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Pass Below Two Hundred Day Moving Average – Should You Sell?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.48 and traded as low as $1.03. Eagle Pharmaceuticals shares last traded at $1.30, with a volume of 940 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a report on Thursday. They issued a “hold” rating on the stock.

Eagle Pharmaceuticals Price Performance

The stock has a fifty day moving average price of $0.93 and a 200-day moving average price of $1.48.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning purchased a new position in Eagle Pharmaceuticals during the 3rd quarter worth $59,000. Jane Street Group LLC purchased a new position in Eagle Pharmaceuticals during the 3rd quarter worth $96,000. DGS Capital Management LLC grew its stake in Eagle Pharmaceuticals by 44.9% during the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 22,239 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Eagle Pharmaceuticals during the 3rd quarter worth $453,000. Finally, RBF Capital LLC grew its stake in Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after buying an additional 14,991 shares during the last quarter. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.